In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|March 25, 2019
Web-based Application Automates HT Experimentation at Pittcon 2019
Author(s)BioPharm International Editors
Katalyst D2D from ACD/Labs enables the design, planning, execution, and analysis of high throughput (HT) experiments. The web-based application was introduced at Pittcon 2019 in Philadelphia, PA.
Advertisement
ACD/Labs, an informatics company that provides analytical and chemical knowledge management solutions for R&D, has developed the Katalyst D2D, a new web-based application for high throughput (HT) experimentation.
Katalyst D2D offers a single interface for HT experimentation and parallel synthesis, from experimental design to final decisions. The company reports that the interface supports the digitization of laboratory tasks, integration with existing informatics systems, lab automation hardware, analytical instrumentation, and automated execution.
The app’s digital environment eliminates the manual transcription currently necessary between systems, as well as the process of gathering and interpreting associated analytical data. This function helps promote data integrity in HT experimentation for reaction optimization, process development, catalyst screening, and scale-up. By streamlining HT workflows, organizations are able to optimize laboratory efficiency, the analysis of array-based chemistry, and the return on investment in HT robotic equipment, according to the company.
Other features include:
- Multi-technique, vendor-agnostic HT analysis enabled by the ACD/Spectrus Platform. Katalyst D2D integrates with analytical instrumentation to support the execution of experiments, followed by the processing and analysis of HT data. Users can easily compare chromatograms, mass spectra, and other analytical data.
- A fully web-based client that meets the informatics requirements of the modern laboratory through convenient user access, facile deployment, and IT support.
The application was showcased for the first time at booth 2116 at Pittcon 2019, Philadelphia, PA, March 17–21, 2019.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5